Table 4.
FRS
|
FRS components | sVCAM1
|
C-RP
|
VEGF
|
SAA
|
IL-6
|
IL-8
|
Mono 4
|
|
---|---|---|---|---|---|---|---|---|---|
β | β | β | β | β | β | β | β | ||
p-value | p-value | p-value | p-value | p-value | p-value | p-value | p-value | ||
0.0081 | 8.7E-5 | 2.6E-7 | 7.9E-4 | −1.6E-8 | −4.6E-4 | 7.7E-4 | 3.0E-3 | ||
<0.001 | 0.04 | 0.13 | 0.01 | 0.69 | 0.9 | 0.88 | 0.12 | ||
Age in years | 6.0E-3 | 7.0E-3 | 6.0E-3 | 7.0E-3 | 7.0E-3 | 7.0E-3 | 7.0E-3 | 6.0E-3 | |
0.002 | <0.001 | 0.001 | 0.003 | <0.001 | <0.001 | <0.001 | 0.001 | ||
Male gender | 0.09 | 0.08 | 0.07 | 0.09 | 0.1 | 0.1 | 0.1 | 0.06 | |
0.06 | 0.08 | 0.04 | 0.04 | 0.04 | 0.03 | 0.04 | 0.18 | ||
Systolic blood pressure | 0.24 | 0.27 | 0.26 | 0.22 | 0.25 | 0.25 | 0.25 | 0.21 | |
0.05 | 0.03 | 0.09 | 0.07 | 0.04 | 0.04 | 0.04 | 0.09 | ||
On antihypertensives | 0.02 | 9.0E-3 | −2.0E-3 | −6.2E-4 | 0.01 | 9.0E-3 | 7.0E-3 | 2.0E-3 | |
0.57 | 0.8 | 0.96 | 0.98 | 0.77 | 0.81 | 0.85 | 0.95 | ||
Current smoker | −1.4E-2 | 3.5E-3 | −1.8E-2 | 8.0E-4 | 5.0E-3 | 6.0E-3 | −7.6E-3 | −4.0E-3 | |
0.71 | 0.92 | 0.63 | 0.98 | 0.9 | 0.88 | 0.84 | 0.93 | ||
Total cholesterol | 0.12 | 0.12 | 0.11 | 0.12 | 0.1 | 0.1 | 0.11 | 6.3E-3 | |
0.09 | 0.11 | 0.12 | 0.09 | 0.16 | 0.14 | 0.13 | 0.36 | ||
HDL | 4.0E-3 | 6.0E-3 | 0.01 | 5.0E-3 | 0.01 | 0.01 | 0.01 | 0.02 | |
0.94 | 0.9 | 0.83 | 0.92 | 0.77 | 0.88 | 0.78 | 0.7 | ||
Diabetes mellitus | 0.05 | 0.08 | 0.09 | 0.08 | 0.09 | 0.09 | 0.09 | 0.05 | |
0.36 | 0.16 | 0.11 | 0.18 | 0.9 | 0.14 | 0.13 | 0.34 |
Far left column lists the component variables of the Framingham risk score (ATPIII). Starting with column two, each column represents a distinct regression model. The second column, FRS ATPIII describes the univariate association of the Framingham risk score ATPIII to CIMT levels. The third column, FRS components, describes adjusted associations of all FRS ATPIII components regressed against CIMT in the same model. The fourth to seventh columns show the values of each candidate immunologic predictors of CIMT modeled singly alongside all FRS ATPIII components. For example, column four shows the association of soluble VCAM1 (sVCAM1) to CIMT value, after adjustment for FRS ATPIII components (Age, Gender, Systolic Blood Pressure, Hypertension Treatment, Current Smoking, Total Cholesterol, HDL and Diabetes). For the adjusted sVCAM1/FRS ATPIII model in column four, the immunologic predictor sVCAM1 remained significantly associated with CIMT (p = 0.04).
Significant associations with CIMT (p < 0.05), or marginally significant associations (0.05 < p < 0.15). Abbreviations: FRS = Framingham risk score (ATPIII), sVCAM1 = soluble vascular cell adhesion molecule 1, C-RP = C reactive protein, VEGF = vasoendothelial growth factor, SAA = serum amyloid alpha, IL-6 = interleukin-6, IL-8 = interleukin-8, Mono 4 = monocyte population 4 (CD14dimCD16− monocytes). HDL = high density lipoprotein.